Products

INCYMO.AI

AI-native

Scale Your User Acquisition with Data-Driven Ads

incymo.ai TelegramMarketing / Ad & Marketing Creatives

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
Subscription model, plan pricing not identified yet
Creators
Anna Zdorenko
@aputini· 130 followers
Launched
5y ago
2021-06-23 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
X accounts@aputini
  • New product launchLaunch

    Jun 23, 2021 · 5y agoWebsite

Third-party reviews & case dossiers

Acquisition breakdowns, engineer reviews & open-source metrics
Starter Story17 team members
2022-10-26Source

These Founders Raised $500K With A Niche AI Tool For Video Game Publishers

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2021-06-23

KeywordMonthly volume
ishimo ai400
colcha tibet350
ryzen 9 7900x que tipo de memoria, macar y velocidad son recomendadas340
como secar sales de desecador50
incymo ai0

Traffic data: Vaneform

Pricing

Public pricing: PaidRaw source text; structured plans are extracted after website capture.

Pages & changes

Tracked since 2026-11-07

Key pages

Weekly snapshots
incymo.ai/ Snapshot 2026-11-10

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does INCYMO.AI get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is INCYMO.AI and what platforms does it support?
INCYMO.AI is catalogued under Ad & Marketing Creatives: Scale Your User Acquisition with Data-Driven Ads. Supported platforms: Web.

Related products in this category

Marketing / Ad & Marketing Creatives

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.